tetano
Editor, Senior Moderator
Sci Rep
. 2021 Feb 4;11(1):3126.
doi: 10.1038/s41598-021-82356-4.
Nanobodies mapped to cross-reactive and divergent epitopes on A(H7N9) influenza hemagglutinin using yeast display
Tiziano Gaiotto[SUP] 1 [/SUP], Walter Ramage[SUP] 1 [/SUP], Christina Ball[SUP] 1 [/SUP], Paul Risley[SUP] 1 [/SUP], George W Carnell[SUP] 2 3 [/SUP], Nigel Temperton[SUP] 2 [/SUP], Othmar G Engelhardt[SUP] 4 [/SUP], Simon E Hufton[SUP] 5 [/SUP]
Affiliations
Abstract
Influenza H7N9 virus continues to cause infections in humans and represents a significant pandemic risk. During the most recent 5th epidemic wave in 2016/17 two distinct lineages with increased human infections and wider geographical spread emerged. In preparation for any future adaptations, broadly reactive antibodies against H7N9 are required for surveillance, therapy and prophylaxis. In this study we have isolated a panel of nanobodies (Nbs) with broad reactivity across H7 influenza strains, including H7N9 strains between 2013 and 2017. We also describe Nbs capable of distinguishing between the most recent high and low pathogenicity Yangtze River Delta lineage H7N9 strains. Nanobodies were classified into 5 distinct groups based on their epitope footprint determined using yeast display and mutational scanning. The epitope footprint of Nbs capable of distinguishing high pathogenic (HP) A/Guangdong/17SF003/2016 from low pathogenic (LP) A/Hong Kong/125/2017 (H7N9) were correlated to natural sequence divergence in the head domain at lysine 164. Several Nbs binding to the head domain were capable of viral neutralisation. The potency of one nanobody NB7-14 could be increased over 1000-fold to 113 pM by linking two Nbs together. Nbs specific for distinct epitopes on H7N9 may be useful for surveillance or therapy in human or veterinary settings.
. 2021 Feb 4;11(1):3126.
doi: 10.1038/s41598-021-82356-4.
Nanobodies mapped to cross-reactive and divergent epitopes on A(H7N9) influenza hemagglutinin using yeast display
Tiziano Gaiotto[SUP] 1 [/SUP], Walter Ramage[SUP] 1 [/SUP], Christina Ball[SUP] 1 [/SUP], Paul Risley[SUP] 1 [/SUP], George W Carnell[SUP] 2 3 [/SUP], Nigel Temperton[SUP] 2 [/SUP], Othmar G Engelhardt[SUP] 4 [/SUP], Simon E Hufton[SUP] 5 [/SUP]
Affiliations
- PMID: 33542302
- DOI: 10.1038/s41598-021-82356-4
Abstract
Influenza H7N9 virus continues to cause infections in humans and represents a significant pandemic risk. During the most recent 5th epidemic wave in 2016/17 two distinct lineages with increased human infections and wider geographical spread emerged. In preparation for any future adaptations, broadly reactive antibodies against H7N9 are required for surveillance, therapy and prophylaxis. In this study we have isolated a panel of nanobodies (Nbs) with broad reactivity across H7 influenza strains, including H7N9 strains between 2013 and 2017. We also describe Nbs capable of distinguishing between the most recent high and low pathogenicity Yangtze River Delta lineage H7N9 strains. Nanobodies were classified into 5 distinct groups based on their epitope footprint determined using yeast display and mutational scanning. The epitope footprint of Nbs capable of distinguishing high pathogenic (HP) A/Guangdong/17SF003/2016 from low pathogenic (LP) A/Hong Kong/125/2017 (H7N9) were correlated to natural sequence divergence in the head domain at lysine 164. Several Nbs binding to the head domain were capable of viral neutralisation. The potency of one nanobody NB7-14 could be increased over 1000-fold to 113 pM by linking two Nbs together. Nbs specific for distinct epitopes on H7N9 may be useful for surveillance or therapy in human or veterinary settings.